PMC9789715_01
Photographs of a patient with moderate-to-severe atopic dermatitis treated for 38 weeks with tralokinumab (A). Baseline; (B) After approximately 18 weeks (following a vaccination for COVID-19); (C) Week 38 (end-of-study).
CCID-15-2825-g0001.jpg
PMC9789715_01_CCID-15-2825-g0001.jpg
f0001
In June 2021, the patient presented to the dermatology department with pruritic eczematous lesions, including the face and neck (Figure 1A, baseline) as well as symptoms of an allergic rhinoconjunctivitis. This was associated with an initial exacerbation of AD (Figure 1B) but good improvement of symptoms by week 32 and up to week 38 (Figure 1C, Week 38).
Changes in symptom scores over the course of 38 weeks in a patient with atopic dermatitis treated with tralokinumab.
CCID-15-2825-g0002.jpg
PMC9789715_01_CCID-15-2825-g0002.jpg
f0002
The evolution of AD symptom and QoL scores from baseline to week 38 are shown in Figure 2. In particular, DLQI improved by 21 points and sleeplessness was completely alleviated by week 38 (Table 1; Figure 2).